Company / Capital Expenditures
Revolution Medicines, Inc. Capital Expenditures History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$16.0M
FY2025
5-year range
$2.6M / $16.0M
FY2021-FY2025
Trend
+55.1%
vs FY2024
Sector context
#46 of 194
Health Care
What the data says
Revolution Medicines, Inc.'s capital expenditures of $16M is higher than 76% of companies in the Health Care sector (FY2025). Capital Expenditures has increased for 5 consecutive years, from $1M in FY2020 to $16M in FY2025.
Based on SEC 10-K filings.
$16M in FY2025 with a 5-year CAGR of +60.5%. Top quartile in the Health Care sector.
Improved from $8M to $16M over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- +76.0%
- 5-Year CAGR
- +60.5%
- 10-Year CAGR
- -
Sector benchmark
-86.4% below sector average
Key checks
Key Insights
- Revolution Medicines, Inc.'s capital expenditures has grown for 5 consecutive years.
- 5-year CAGR of +60.5%, indicating consistent growth.
- In FY2025, capital expenditures increased 55.1% year-over-year.
- Ranks #46 out of 194 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $16.0M | +55.1% |
| FY2024 | $10.3M | +33.4% |
| FY2023 | $7.7M | +163.5% |
| FY2022 | $2.9M | +13.3% |
| FY2021 | $2.6M | +72.7% |
| FY2020 | $1.5M | -42.1% |
| FY2019 | $2.6M | +72.7% |
| FY2018 | $1.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026